Clinical trial
A Phase I Trial of Farnesyltransferase Inhibitor, R115777 (NSC # 702818) and Radiotherapy in Patients With Non-Small Cell Lung Cancer
NCT00025480 is registered in ClinicalTrials.gov with Abramson Cancer Center at Penn Medicine as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Trial of Farnesyltransferase Inhibitor, R115777 (NSC # 702818) and Radiotherapy in Patients With Non-Small Cell Lung Cancer
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- August 31, 2001
- Completion date
- Not reported
- Enrollment
- 12 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
lung cancer